Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
1997 ◽
Vol 33
◽
pp. S231
◽
Keyword(s):
Phase Ii
◽